Schering-Plough Research Institute

Schering-Plough Research Institute
Name	Schering-Plough Research Institute
Established	1971
Parent	Schering-Plough
Location	Kenilworth, New Jersey
Industry	Pharmaceutical industry
Focus	Drug discovery

Schering-Plough Research Institute. It was the dedicated research and development division of the global pharmaceutical corporation Schering-Plough, established to centralize and drive its innovative drug discovery efforts. The institute played a pivotal role in advancing treatments across multiple therapeutic areas, including infectious diseases, central nervous system disorders, and oncology. Its work culminated in several blockbuster pharmaceuticals and significant contributions to medical science before its parent company's merger with Merck & Co. in 2009.

History

The institute was formally established in 1971, consolidating the research activities of the historic Schering Corporation, which traced its roots to a Berlin-based apothecary founded by Ernst Schering in 1851. This reorganization under the Schering-Plough name, following the 1971 merger with Plough, Inc., aimed to create a powerhouse for pharmaceutical innovation. Throughout the late 20th century, it expanded its scientific footprint through strategic acquisitions, including the Key Pharmaceuticals purchase in 1986, which bolstered its expertise in respiratory medicine. The institute's history concluded when its parent company completed a monumental merger with Merck & Co. in November 2009, integrating its research pipelines and scientific talent into the larger entity.

Research and development

The institute's R&D efforts were organized into focused therapeutic areas, with major programs in anti-infectives, central nervous system disorders, cardiovascular and metabolic disease, and oncology. It maintained a strong legacy in antibiotic research, building upon the legacy of early Schering Corporation discoveries. Scientists at the institute utilized advanced techniques in medicinal chemistry, molecular biology, and pharmacology to identify and optimize novel drug candidates. Collaborative research with external organizations like the National Institutes of Health and academic institutions such as Harvard University was also a key component of its strategy to explore new biological targets and therapeutic modalities.

Key products and discoveries

The institute was responsible for the discovery and development of numerous important medicines. Its most notable success was the blockbuster antihistamine Claritin (loratadine), which became a flagship product for Schering-Plough. Other significant contributions included the interferon therapy Intron A (interferon alfa-2b) for conditions like hepatitis B and certain cancers, and the pegylated interferon Pegintron. In the realm of infectious disease, it developed the antifungal Noxafil (posaconazole) and the antibiotic Avelox (moxifloxacin), the latter in partnership with Bayer. The cholesterol-lowering drug Zetia (ezetimibe), developed in collaboration with the Merck & Co. that would later acquire the company, also emerged from its research pipeline.

Facilities and locations

The primary research headquarters was located in Kenilworth, New Jersey, a major hub for the global pharmaceutical industry. This campus housed extensive laboratories for discovery and early-stage development. Additional significant R&D facilities were operated in Union, New Jersey, and Lafayette, Colorado. Internationally, the institute maintained important research centers in Brussels, Belgium, and Milan, Italy, supporting its global clinical development and regulatory efforts. These sites were critical for conducting multinational clinical trials and fostering collaborations with the European scientific community.

Leadership and organization

The institute was led by a series of prominent scientific executives, including research presidents who reported directly to the Chief Executive Officer of Schering-Plough. Key figures such as Stephen Friend and Robert J. Spiegel held senior roles, guiding research strategy and portfolio management. Its organizational structure integrated discovery research, preclinical development, and early clinical research, often working in close coordination with the commercial divisions of Schering-Plough. Following the merger with Merck & Co., much of its leadership and scientific staff were integrated into the research divisions of the combined company, known as Merck Sharp & Dohme outside the United States.

Legacy and impact

The legacy of the institute is evident in its lasting contributions to pharmacotherapy, particularly in allergy, virology, and antifungal treatment. Its innovative work on Claritin and Intron A defined standards of care in their respective fields and generated significant revenue that funded further research. The integration of its assets into Merck & Co. created one of the world's largest pharmaceutical research organizations, combining pipelines in areas like hepatitis C and oncology. The institute also fostered a generation of pharmaceutical scientists whose work continued to influence drug discovery at Merck & Co. and across the broader industry, cementing its place in the history of American industrial research.

Category:Pharmaceutical research institutes Category:Schering-Plough Category:Defunct medical and health organizations based in New Jersey